These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 20144869)
21. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation. Arhancet GB; Walker DP; Metz S; Fobian YM; Heasley SE; Carter JS; Springer JR; Jones DE; Hayes MJ; Shaffer AF; Jerome GM; Baratta MT; Zweifel B; Moore WM; Masferrer JL; Vazquez ML Bioorg Med Chem Lett; 2013 Feb; 23(4):1114-9. PubMed ID: 23260349 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prostaglandin E synthase-1 expression. Guerrero MD; Aquino M; Bruno I; Terencio MC; Paya M; Riccio R; Gomez-Paloma L J Med Chem; 2007 May; 50(9):2176-84. PubMed ID: 17407277 [TBL] [Abstract][Full Text] [Related]
24. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. Rörsch F; Wobst I; Zettl H; Schubert-Zsilavecz M; Grösch S; Geisslinger G; Schneider G; Proschak E J Med Chem; 2010 Jan; 53(2):911-5. PubMed ID: 20025212 [TBL] [Abstract][Full Text] [Related]
25. Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. Koeberle A; Bauer J; Verhoff M; Hoffmann M; Northoff H; Werz O Biochem Biophys Res Commun; 2009 Oct; 388(2):350-4. PubMed ID: 19665000 [TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1). Rörsch F; Buscató E; Deckmann K; Schneider G; Schubert-Zsilavecz M; Geisslinger G; Proschak E; Grösch S J Med Chem; 2012 Apr; 55(8):3792-803. PubMed ID: 22449023 [TBL] [Abstract][Full Text] [Related]
27. Synthesis and SAR study of imidazoquinolines as a novel structural class of microsomal prostaglandin E₂ synthase-1 inhibitors. Shiro T; Takahashi H; Kakiguchi K; Inoue Y; Masuda K; Nagata H; Tobe M Bioorg Med Chem Lett; 2012 Jan; 22(1):285-8. PubMed ID: 22137787 [TBL] [Abstract][Full Text] [Related]
28. Curcumin suppresses interleukin 1beta-mediated microsomal prostaglandin E synthase 1 by altering early growth response gene 1 and other signaling pathways. Moon Y; Glasgow WC; Eling TE J Pharmacol Exp Ther; 2005 Nov; 315(2):788-95. PubMed ID: 16081677 [TBL] [Abstract][Full Text] [Related]
29. Murine mPGES-1 3D structure elucidation and inhibitors binding mode predictions by homology modeling and site-directed mutagenesis. Corso G; Coletta I; Ombrato R J Chem Inf Model; 2013 Jul; 53(7):1804-17. PubMed ID: 23789712 [TBL] [Abstract][Full Text] [Related]
31. Identification and development of mPGES-1 inhibitors: where we are at? Chang HH; Meuillet EJ Future Med Chem; 2011 Nov; 3(15):1909-34. PubMed ID: 22023034 [TBL] [Abstract][Full Text] [Related]
32. PGE synthase inhibitors as an alternative to COX-2 inhibitors. Jachak SM Curr Opin Investig Drugs; 2007 May; 8(5):411-5. PubMed ID: 17520870 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of novel myrtucommulones and structural analogues that target mPGES-1 and 5-lipoxygenase. Wiechmann K; Müller H; Huch V; Hartmann D; Werz O; Jauch J Eur J Med Chem; 2015 Aug; 101():133-49. PubMed ID: 26123643 [TBL] [Abstract][Full Text] [Related]
34. Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen. He S; Li C; Liu Y; Lai L J Med Chem; 2013 Apr; 56(8):3296-309. PubMed ID: 23527738 [TBL] [Abstract][Full Text] [Related]
35. Toward the management of inflammation: recent developments of mPGES-1 inhibitors. Dallaporta M; Pecchi E; Thirion S; Jean A; Troadec JD Recent Pat CNS Drug Discov; 2010 Jan; 5(1):70-80. PubMed ID: 19751209 [TBL] [Abstract][Full Text] [Related]
36. Novel 1,3,4-oxadiazole derivatives as highly potent microsomal prostaglandin E Gür Maz T; Dahlke P; Gizem Ergül A; Olğaç A; Jordan PM; Çalışkan B; Werz O; Banoglu E Bioorg Chem; 2024 Jun; 147():107383. PubMed ID: 38653151 [TBL] [Abstract][Full Text] [Related]
37. Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1. Wiegard A; Hanekamp W; Griessbach K; Fabian J; Lehr M Eur J Med Chem; 2012 Feb; 48():153-63. PubMed ID: 22209272 [TBL] [Abstract][Full Text] [Related]
38. 3D-QSAR study of microsomal prostaglandin E2 synthase (mPGES-1) inhibitors. San Juan AA; Cho SJ J Mol Model; 2007 May; 13(5):601-10. PubMed ID: 17390157 [TBL] [Abstract][Full Text] [Related]
39. Molecular docking and competitive binding study discovered different binding modes of microsomal prostaglandin E synthase-1 inhibitors. He S; Lai L J Chem Inf Model; 2011 Dec; 51(12):3254-61. PubMed ID: 22077876 [TBL] [Abstract][Full Text] [Related]
40. Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid. Hieke M; Greiner C; Dittrich M; Reisen F; Schneider G; Schubert-Zsilavecz M; Werz O J Med Chem; 2011 Jul; 54(13):4490-507. PubMed ID: 21591611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]